NasdaqGS:ZEAL

Stock Analysis Report

Executive Summary

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Zealand Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.4%

ZEAL

3.1%

US Biotechs

0.07%

US Market


1 Year Return

101.5%

ZEAL

-1.6%

US Biotechs

8.9%

US Market

Return vs Industry: ZEAL exceeded the US Biotechs industry which returned -1.6% over the past year.

Return vs Market: ZEAL exceeded the US Market which returned 8.9% over the past year.


Shareholder returns

ZEALIndustryMarket
7 Day1.4%3.1%0.07%
30 Day-0.7%0.2%-0.3%
90 Day11.2%0.9%-1.6%
1 Year101.5%101.5%-0.7%-1.6%11.3%8.9%
3 Yearn/a18.9%14.7%46.3%36.8%
5 Yearn/a-1.8%-6.6%62.1%44.3%

Price Volatility Vs. Market

How volatile is Zealand Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Zealand Pharma undervalued compared to its fair value and its price relative to the market?

10.93x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ZEAL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ZEAL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZEAL is good value based on its PE Ratio (10.9x) compared to the Biotechs industry average (16.4x).

PE vs Market: ZEAL is good value based on its PE Ratio (10.9x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: ZEAL is poor value based on its PEG Ratio (5.2x)


Price to Book Ratio

PB vs Industry: ZEAL is overvalued based on its PB Ratio (6.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Zealand Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

2.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZEAL's forecast earnings growth (2.1% per year) is below the savings rate (2.7%).

Earnings vs Market: ZEAL's earnings (2.1% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: ZEAL's earnings are forecast to grow, but not significantly.

Revenue vs Market: ZEAL's revenue (57% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: ZEAL's revenue (57% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZEAL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Zealand Pharma performed over the past 5 years?

43.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ZEAL has become profitable over the past 5 years, growing earnings by 43.3% per year.

Accelerating Growth: ZEAL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ZEAL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: ZEAL's Return on Equity (54.2%) is considered outstanding.


Return on Assets

ROA vs Industry: ZEAL has a higher Return on Assets than the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: ZEAL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Zealand Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ZEAL's short term assets (DKK1.2B) exceeds its short term liabilities (DKK262.6M)

Long Term Liabilities: ZEAL has no long term liabilities


Debt to Equity History and Analysis

Debt Level: ZEAL is debt free.

Reducing Debt: ZEAL had no debt 5 years ago.

Debt Coverage: ZEAL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ZEAL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: ZEAL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ZEAL's debt is covered by short term assets.


Next Steps

Dividend

What is Zealand Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.2%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ZEAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ZEAL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ZEAL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZEAL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZEAL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Zealand Pharma's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Emmanuel Dulac (49yo)

0.5yrs

Tenure

0

Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice Presiden ...


Management Age and Tenure

1.0yrs

Average Tenure

49yo

Average Age

Experienced Management: ZEAL's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Age and Tenure

7.9yrs

Average Tenure

64yo

Average Age

Experienced Board: ZEAL's board of directors are considered experienced (7.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Hanne Bak (66yo)

    Senior Project Director

    • Tenure: 3.5yrs
    • Compensation: ø300.00k
  • Niels Mørk

    Head of Bioanalysis

    • Tenure: 0yrs
  • Jens Mikkelsen

    Head of Molecular Pharmacology

    • Tenure: 0yrs
  • Marino Garcia (53yo)

    Senior Vice President of Corporate & Business Development

    • Tenure: 1yrs
  • Søren Keller

    Head of Legal Affairs

    • Tenure: 5.5yrs
  • Adam Steensberg (45yo)

    Executive VP and Chief Medical & Development Officer

    • Tenure: 0.8yrs
  • Emmanuel Dulac (49yo)

    CEO & President

    • Tenure: 0.5yrs
  • Ivan Møller (47yo)

    Senior Vice President of Technical Development & Operations

    • Tenure: 1.6yrs
  • Lani Morvan

    Investor Relations & Communications Officer

    • Tenure: 0yrs
  • Rie Hansen

    Interim Chief Scientific Officer & VP of Research

    • Tenure: 0.2yrs

Board Members

  • Leon Kruimer (61yo)

    Independent Director

    • Tenure: 0.5yrs
  • Alain Munoz (70yo)

    Co-Chair of the Clinical & Scientific Advisory Board & Director

    • Tenure: 7.9yrs
    • Compensation: ø350.00k
  • Martin Nicklasson (64yo)

    Independent Chairman of the Board

    • Tenure: 4.5yrs
    • Compensation: ø750.00k
  • Ake Lernmark (74yo)

    Member of Advisory Board

    • Tenure: 7.9yrs
  • Tyge Korsgaard (62yo)

    Board Observer

    • Tenure: 0yrs
  • Bernard Charbonnel

    Member of Advisory Board

    • Tenure: 7.9yrs
  • Richard Pratley

    Member of Advisory Board

    • Tenure: 7.9yrs
  • Paul Dorian

    Member of Advisory Board

    • Tenure: 7.9yrs
  • Hanne Bak (66yo)

    Senior Project Director

    • Tenure: 3.5yrs
    • Compensation: ø300.00k
  • Kirsten Drejer (63yo)

    Independent Vice Chairman

    • Tenure: 0.5yrs
    • Compensation: ø200.00k

Company Information

Zealand Pharma A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zealand Pharma A/S
  • Ticker: ZEAL
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø6.623b
  • Listing Market Cap: ø987.710m
  • Shares outstanding: 35.80m
  • Website: https://www.zealandpharma.com

Number of Employees


Location

  • Zealand Pharma A/S
  • Sydmarken 11
  • Søborg
  • Copenhagen
  • Capital Region of Denmark
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZEALCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKNov 2010
0NZULSE (London Stock Exchange)YesOrdinary SharesGBDKKNov 2010
22ZDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2010
ZLDP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2010
ZEALCBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBDKKNov 2010
ZEALNasdaqGS (Nasdaq Global Select)ADR EACH REP 1 ORD SHS SPONUSUSDAug 2017
22ZADB (Deutsche Boerse AG)ADR EACH REP 1 ORD SHS SPONDEEURAug 2017

Biography

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on g ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:33
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.